Bitter T, Horstkotte D, Oldenburg O
Klinik für Kardiologie, Herz- und Diabeteszentrum Nordrhein Westfalen, Ruhr-Universität Bochum, Bad Oeynhausen.
Dtsch Med Wochenschr. 2011 Mar;136(9):431-5. doi: 10.1055/s-0031-1274525. Epub 2011 Feb 22.
In patients with cardiac disease growing interests have been centered on concomitant co-morbidities such as sleep disordered breathing (SDB). Obstructive sleep apnoea (OSA) as well as Cheyne-Stokes Respiration (CSR) have been recognized as relevant co-morbidities that are highly prevalent and associated with an impaired prognosis. As a known consequence from recurrent hypoxaemias and an increased sympathetic activity, SDB promotes structural myocardial changes and potentially triggers cardiac arrhythmias. Several investigations thus reported an increasing frequency of cardiac arrhythmias among patients with either OSA or CSR. Sufficiently suppressing SDB by adequate therapies seems to ameliorate its arrhythmogenic impact. However, especially for CSR data from randomized, controlled trial are urgently awaited to definitely answer this question.
在患有心脏病的患者中,人们越来越关注诸如睡眠呼吸紊乱(SDB)等合并症。阻塞性睡眠呼吸暂停(OSA)以及潮式呼吸(CSR)已被认为是相关的合并症,它们非常普遍且与预后不良相关。作为反复低氧血症和交感神经活动增加的已知后果,SDB会促进心肌结构改变并可能引发心律失常。因此,多项研究报告称,OSA或CSR患者的心律失常发生率不断增加。通过适当的治疗充分抑制SDB似乎可以减轻其致心律失常的影响。然而,尤其是对于CSR,迫切需要来自随机对照试验的数据来明确回答这个问题。